Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

New Theranostic Biomarkers of Intraductal Mucinous Neoplasm (IPMN) Progression to Pancreatic Cancer for Patients' Outcome Improvement

NCT06574373 is registered in ClinicalTrials.gov with Fondazione Policlinico Universitario Agostino Gemelli IRCCS as lead sponsor.

NCT NCT06574373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06574373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
New Theranostic Biomarkers of Intraductal Mucinous Neoplasm (IPMN) Progression to Pancreatic Cancer for Patients' Outcome Improvement
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Overall status
Recruiting
Start date
May 29, 2025
Completion date
December 31, 2026
Enrollment
3,600 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ipmn, pancreatic